| 1. |
Probiotics promise much, but development of the field is hampered by a lack of knowledge, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
An independent US-based panel has confirmed that alteplase is beneficial for acute stroke, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Statins: age and the treatment gap |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Cost of migraine therapy gives US society a headache |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 5-6
&NA;,
Preview
|
|
摘要:
Migraine is a neurological disorder with a high prevalence, affecting approximately 28 million individuals in the US annually. Considering this high prevalence, it is no surprise that migraine represents a substantial cost burden for society, both in terms of direct medical costs and costs associated with lost productivity and absenteeism. Several effective migraine-specific drugs have become widely available in recent years, and their cost effectiveness is of great interest to decision-makers and healthcare payers alike. Some of these important issues were the focus of several studies presented as poster and oral sessions at the 8th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research [Arlington, US; May 2003].
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Which anaesthetic worth it for day surgery in the UK? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Pneumococcal vaccination rates and physician-patient discussion regarding such vaccination can be significantly improved |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Factor IX gene therapy for haemophilia B |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
XL 119*has demonstrated encouraging survival results in patients with biliary cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Pemetrexed in advanced malignant pleural mesothelioma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Tadalafil up with the best in erectile dysfunction |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1391,
2003,
Page 11-12
R Carlson,
Preview
|
|
摘要:
The phosphodiesterase (PDE) type 5 inhibitor tadalafil ['Cialis'] is effective in the treatment of even severe erectile dysfunction, according to results from a US study reported at the 98th Annual Meeting of the American Urological Association [Chicago, US; April−May 2003]. A multicentre study showed that improvement in erections, as measured by a global assessment questionnaire (GAQ), were reported by 79% of tadalafil recipients, compared with 19% of patients in the placebo group. Tadalafil was well tolerated, both in this study, and also in a long-term safety study presented at the meeting. Importantly, another study showed that tadalafil was unlikely to adversely affect patients' fertility, as levels of reproductive hormones, sperm counts and sperm motility were unchanged after administration of the drug.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
